It is important, however, that the wall of the cyst, composed of a stratified squamous epithelium which is the only living, growing part of the neoplasm, be removed completely in order to prevent recurrence. Simple evacuation of the cyst will not suffice.

Giant intracranial epidermoids: is total removal feasible?

*Emad Aboud, MD,1 Mohammad Abolfotoh, MD, PhD,2,4 Svetlana Pravdenkova, MD, PhD,1 Abdulkerim Gokoglu, MD,2 Murat Gokden, MD,3 and Ossama Al-Mefty, MD2

1Arkansas Neuroscience Institute; 2Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas; 3Department of Neurosurgery, Brigham and Women’s Hospital, Harvard University, School of Medicine, Boston, Massachusetts; and 4Department of Neurosurgery, Ain Shams University, Cairo, Egypt

OBJECT Epidermoid tumors arise from misplaced squamous epithelium and enlarge through the accumulation of desquamated cell debris. Optimal treatment consists of total removal of the capsule; therefore, giant and multicompartamental tumors are particularly challenging. A conservative attitude in handling the tumor capsule is common given concerns about capsule adherence to neurovascular structures, and thus the possibility of recurrence is accepted with the intent of minimizing complications. This study focuses on the outcome of surgery in patients with giant epidermoid tumors for which total capsule removal was the aim.

METHODS The authors conducted a retrospective analysis of all patients with giant epidermoid tumors treated by the senior author (O.A.), who pursued total removal of the capsule through skull base approaches. Patients were divided into 2 groups: one including patients with de novo tumors and the other consisting of patients who presented with recurrent tumors.

RESULTS Thirty-four patients had undergone 46 operations, and the senior author performed 38 of these operations in the study period. The average tumor dimensions were 55 × 36 mm, and 25 tumors had multicompartamental extensions. Total removal of the tumor and capsule was achieved with the aid of the microscope in 73% of the 26 de novo cases but in only 17% of the 12 recurrent tumor cases. The average follow-up among all patients was 111 months (range 10–480 months), and the average postsurgical follow-up was 56.8 months (range 6–137 months). There were 4 recurrences in the de novo group, and every case had had a small piece of tumor capsule left behind. One patient died after delayed rupture of a pseudoaneurysm. In the de novo group, the average preoperative Karnofsky Performance Scale (KPS) score was 71.42%, which improved to 87.14% on long-term follow-up. In the group with recurrences, the KPS score also improved on long-term follow-up, from 64.54% to 84.54%. In the de novo group, 3 cases (11.5%) had permanent cranial nerve deficits, and 4 cases (15.4%) had a CSF leak. In the recurrence group, 3 cases (25%) had new, permanent cranial nerve deficits, and 1 (8.3%) had a CSF leak. Two patients in this group developed hydrocephalus and required a shunt.

CONCLUSIONS Total removal of the capsule of giant epidermoid tumors was achieved in 73% of patients with de novo tumors and was associated with improved function, low morbidity and mortality, and a lower risk of recurrence. Surgery in patients with recurrent tumors was associated with higher morbidity and persistence of the disease.

http://thejns.org/doi/abs/10.3171/2014.11.JNS1481

KEY WORDS brain tumor; epidermoid cyst; epithelial capsule; skull base approaches; endoscopic techniques; microsurgical removal; oncology

It is important, however, that the wall of the cyst, composed of a stratified squamous epithelium which is the only living, growing part of the neoplasm, be removed completely in order to prevent recurrence. Simple evacuation of the cyst will not suffice.

Epidermoids, known as the “pearly tumor,” are benign, slow-growing lesions that constitute 1.2% of brain tumors. They are commonly believed to arise from misplaced stratified squamous epithelium during closure of the neural tube. They enlarge by accumulating desquamated epidermal cell debris and insinuate into the subarachnoid space, at times extending into multiple compartments. By the time a patient presents for medical attention, the epidermoid may have reached a giant size.5,9,14,31,43,57 Although many authors acknowledge that the ultimate goal...
of treatment is total removal of the capsule, a conservative attitude has prevailed because the capsule adheres to neurovascular structures at the cranial base (arteries, perforators, cranial nerves [CNs], and brainstem). Thus, many surgeons are inclined to leave part of the capsule behind, thereby accepting the risk of recurrence.\textsuperscript{4,6,23,40,44,46,56} Others advocate only a decompressive procedure with subtotal removal.\textsuperscript{2,10,38} Owing to the slow linear growth of the epithelium and the rate at which debris accumulates,\textsuperscript{5} recurrences are claimed to be late and are frequently underreported.

Regardless of the argument that the capsule is a mere remnant of epithelium, some epidermoids grow faster than natural epithelium and enlarge or recur through cellular proliferation, and thus act as a true benign neoplasm\textsuperscript{53} and even occasionally a malignant one.\textsuperscript{11,27,36,37,47,53} with leptomeningeal metastasis from the intracranial malignant transformation of an epidermoid tumor.\textsuperscript{25,33} Furthermore, malignant conversion has been reported as the recurrence of a previously benign epidermoid.\textsuperscript{21,53,54} Several investigators have commented that since the capsule is the “living portion” of the tumor,\textsuperscript{78,12,34} recurrence is inevitable with a residual capsule. Total removal of the capsule, which is now possible with microsurgical techniques, can prevent recurrence, and if only a minute portion of the capsule is overlooked during surgery, recurrence may at least be long delayed. This approach minimizes the complications associated with repeated surgery and subsequently improves patient outcome and quality of life. Furthermore, such an approach eliminates neoplastic or even malignant transformations.

The task of eliminating the epidermoid capsule is admittedly challenging, particularly in patients with giant tumors that extend into multiple compartments. This study is a retrospective analysis of a series of patients harboring giant epidermoid tumors that expanded into multiple compartments. They underwent surgery performed by the senior author (O.A.) with the goal of total removal of the capsule. This report aims to address the feasibility of total removal of the capsule of giant epidermoid tumors and its impact on complications and outcome. We postulated that total removal of the capsule not only prevents or delays recurrence but also minimizes complications and improves long-term outcome.

**Methods**

We conducted a retrospective study of all patients with intracranial epidermoid tumors surgically treated by the senior author (O.A.) in the period from 1987 through 2013. The aim of treatment was total removal of the tumor capsule. We reviewed each patient’s clinical findings, images, operative procedures, postoperative outcome, and follow-up. As this is a retrospective study, it has the shortcomings of such a method, including selection bias, a span of more than 2 decades, and nonadjudicated outcome analysis. But the rarity of these tumors and the lengthy time period needed for study leads to such a method.

Patients were divided into 2 groups: those with de novo tumors without prior treatment and those having a tumor recurrence after surgery at another institution. In calculating the total number of surgical procedures performed by the senior author in all patients, we counted second operations that were performed in patients in the de novo group, bringing the total to 38. Tumor size was measured in two dimensions on MRI studies and was calculated using Centricity software (Centricity, GE Healthcare) and OsiriX for the Macintosh (OsiriX).

**Results**

The series comprised 34 patients, 18 males and 16 females, with an average age of 35.77 years (range 9–67 years) at the first surgery performed by any surgeon. Twenty-six patients had de novo tumors without prior treatment, and 8 patients had a recurrence after surgery at another institution. The average age at surgery for recurrence (12 cases) was 44.9 years (range 20–63 years; Fig. 1). A total of 38 operations were performed for resection, 26 in patients with de novo tumors and 12 in those with recurrences (8 patients presented to us with recurrences, and 4 had recurrences after our initial surgery).

The average size of the tumor before surgery in the de novo group was 55.03 × 35.48 mm, while in the recurrence group it was 54.38 × 38.73 mm. The largest tumor measured 102 × 76 mm, while the smallest was 12 × 26 mm. Before any surgery, 72% of the tumors had at least 1 diameter ≥ 40 mm. These tumors had primary locations with extensions into various compartments in the same or adjacent cranial fossa. Details of the primary tumor locations and extensions for the 2 groups are summarized in Figs. 2 and 3.

**Clinical Findings**

The duration of symptoms in this series varied widely, from 5 days with hydrocephalus to a 30-year history of headache. The average duration of symptoms was 28.43 months. Symptoms also varied according to tumor location. Cranial nerve involvement was common in tumors in the cerebellopontine angle, while deteriorating vision was the most common presentation for patients with primary or secondary suprasellar epidermoids. Headache was common for tumors in any location and ranged from severe and

**FIG. 1.** The age distribution of patients at presentation. SD = standard deviation.
FIG. 2. De novo tumors involved 26 surgeries. Pie chart indicates distribution of primary tumor locations. Middle fossa refers to both the middle fossa and the temporal fossa. Bar graphs indicate the frequency of areas of extension of the cerebellopontine angle (right graph) and prepontine cistern (left graph) tumors. Temporal fossa refers to both the middle fossa and the temporal fossa. Figure is available in color online only.

FIG. 3. Recurrent tumors involved 12 surgeries. Pie chart indicates distribution of primary tumor locations. Bar graphs indicate the frequency of areas of extension of the cerebellopontine angle (right graph) and the suprasellar (left graph) tumors. Figure is available in color online only.
refractory to pain medication, to mild and lasting for years. The main symptoms at presentation are listed in Table 1.

**Imaging**

For all cases, we reviewed preoperative, postoperative, and follow-up MR images with and without gadolinium enhancement and diffusion-weighted images, as well as CT scans. Findings differed between the de novo and recurrent groups. Keratin contents were all positive in the diffusion sequences. Faint capsule enhancement was present in only 2 cases (7.7%) in the de novo group, while the capsule enhanced significantly in 5 cases (41.7%) in the recurrent group. Septation of the tumor was rare in patients with de novo tumors, occurring in only 4 cases (15.4%), while it occurred in 5 cases (41.7%) of recurrent tumor. At the second recurrence, all cases showed an enhanced capsule and multiloculation.

**Surgical Technique**

To achieve a wide exposure, to access all parts of the lesion, and to pursue total removal of the capsule, we used the skull base approaches listed in Table 2 and shown in Fig. 4. Because several CNs were compressed, involved, encased, or adherent to the brainstem (at times bilaterally), we used intraoperative neurophysiological monitoring, including somatosensory evoked potentials and brainstem auditory evoked responses, and extensive individual monitoring of all potentially involved CNs. Neuronavigation has been used routinely since 1993.

After evacuating the keratin contents with controlled suction, the surgeon performs meticulous microdissection with two hands to tease adherent capsule from the arachnoid layer, thereby freeing the neurovascular structures. Traction is avoided and sharp microdissection is used (Fig. 5). In all de novo cases, a plane of dissection can be developed between the capsule and a compressed overlying arachnoid; it is essential to identify and confirm this plane and preserve it as long as possible. When it is unclear which portion is tumor capsule and which is arachnoid, a frozen section is sent for analysis (Fig. 6). If this analysis shows arachnoid only and no epithelial tissue, there is no need to pursue the membrane further.

In most of the patients with de novo tumors, the capsule was thin, avascular, or fibrotic and was easily dissected from neurovascular structures; however, it adhered to neurovascular structures in some cases (Fig. 7). Small perforators can traverse the contents of the cyst, perhaps because of the wrinkling or enfolding of the epithelial layer. In all surgeries for recurrent epidermoid tumors in this series, the capsule was thick and adhered to surrounding structures. We also noticed that the capsule became increasingly thick and fibrous with subsequent recurrences, a situation that can lead to the formation of loculated cysts of CSF or yellowish fluid that can compress surrounding structures.

The endoscope was used in 13 operations. It can reveal remnants of tumor hidden around the corner from the direct microscopic axis or into the foraamina (internal auditory meatus, Meckel’s cave, and jugular foramen). It assists in reaching a supratentorial extension when a purely posterior fossa approach is used (Fig. 5F).

The surgical site is walled off to minimize the spread of irritating substances and the risk of aseptic meningitis. Irrigation is used after resection is complete, and any debris is suctioned away. High doses of steroids are administered intraoperatively and slowly tapered over 2 weeks after surgery. Postoperative MRI is performed with diffusion sequences to verify gross removal of the contents and as a baseline for follow-up (Fig. 8).

**Extent of Resection**

Our evaluation of resection was based on the surgeon’s notes in the operative reports regarding the extent of capsule removal. Microscopic total removal of the capsule was achieved in 19 cases (73%) in the de novo group but in only 2 (16.7%) of the 12 surgeries on recurrent tumors. Unfortunately, there is no postoperative imaging modality or tool that can be used to evaluate the degree of capsule resection. Diffusion weighted imaging confirms total removal of the contents, but postoperative DWI always showed bright signal in patients with a residual capsule from which all debris was thought to be totally removed (Table 3), probably because of microscopic flakes attached to the residual capsule.

---

**TABLE 1. Signs and symptoms at presentation in 34 patients**

<table>
<thead>
<tr>
<th>Signs &amp; Symptoms</th>
<th>% of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache (variable degrees)</td>
<td>42</td>
</tr>
<tr>
<td>Weakness (variable distributions)</td>
<td>20</td>
</tr>
<tr>
<td>Hearing loss (variable degree)</td>
<td>18</td>
</tr>
<tr>
<td>Diplopia</td>
<td>16</td>
</tr>
<tr>
<td>Gait disturbance &amp; ataxia</td>
<td>12</td>
</tr>
<tr>
<td>Trigeminal neuralgia</td>
<td>12</td>
</tr>
<tr>
<td>Facial numbness</td>
<td>10</td>
</tr>
<tr>
<td>Facial weakness (variable degree)</td>
<td>10</td>
</tr>
<tr>
<td>Vertigo &amp; tinnitus</td>
<td>8</td>
</tr>
<tr>
<td>Swallowing difficulty</td>
<td>8</td>
</tr>
<tr>
<td>Seizures</td>
<td>6</td>
</tr>
<tr>
<td>Deterioration of vision</td>
<td>6</td>
</tr>
<tr>
<td>Hydrocephalus</td>
<td>4</td>
</tr>
<tr>
<td>Hemifacial spasm</td>
<td>2</td>
</tr>
</tbody>
</table>

**TABLE 2. Approaches used in 38 surgeries for epidermoid tumors**

<table>
<thead>
<tr>
<th>Surgical Approach</th>
<th>No. of Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transmastoid retrosigmoid</td>
<td>12</td>
</tr>
<tr>
<td>Combined petrosal</td>
<td>8</td>
</tr>
<tr>
<td>Posterior petrosal</td>
<td>6</td>
</tr>
<tr>
<td>Cranio-orbital zygomatic</td>
<td>5</td>
</tr>
<tr>
<td>Transcondylar</td>
<td>2</td>
</tr>
<tr>
<td>Pterional</td>
<td>2</td>
</tr>
<tr>
<td>Total petrosectomy</td>
<td>1</td>
</tr>
<tr>
<td>Zygomatic</td>
<td>1</td>
</tr>
<tr>
<td>Anterior petrosal</td>
<td>1</td>
</tr>
</tbody>
</table>

* Used twice in the same patient for 2 recurrences.
Outcome

The average follow-up was 111 months (range 10–480 months), and the average postsurgical follow-up was 56.8 months (range 6–137 months). There was one perioperative death (de novo group) from delayed rupture of a pseudoaneurysm after a suture repair of the A1 segment. In the de novo group, the average Karnofsky Performance Scale (KPS) score before surgery was 71.42% (range 50%–90%), which improved to 76.66% immediately after surgery and further improved to 87.14% during the follow-up period. In the group with recurrences, the average KPS score before surgery was 64.54% (range 60%–80%). After surgery, this score improved immediately to 71.81% and continued to improve to 84.54% during the follow-up period. Table 4 shows the KPS scores, which were available in 31 patients.

Among the 26 de novo cases, new, permanent CN deficits occurred in 3 cases (11.5%). Transient CN deficits occurred in 9 cases (34.6%) and CSF leakage in 4 cases (15.4%). Three patients with CSF leakage required reexploration and 1 patient had a seizure.

In the recurrence group, new, permanent CN deficits occurred in 3 cases (25%), and transient CN deficits oc-
Recurrence was diagnosed when progressive symptoms were associated with an increase in tumor size with a bright signal on DWI or extension into a new compartment. At recurrence, the tumor frequently changed its primary location, as it extended from the periphery of the original resection to other areas. Moreover, it showed more frequent capsule wall enhancement and multiloculations (Fig. 9). In the de novo group, 4 cases (15.4%) had a recurrence, while 5 cases (41.7%) in the recurrence group had a subsequent recurrence. In the de novo cases, we performed a Kaplan-Meier estimate to compare the rate of recurrence between 2 groups divided according to capsule removal: Group 1 had no residual capsule and Group 2 had a residual capsule (Fig. 10).

Follow-up was calculated for each operation. It was relatively short for patients with repeated recurrences, at an average of 56 months. The average calculated among all patients was 111 months. The average recurrence-free survival period after the first surgery was 121.5 months (range 33–150 months), while the recurrence-free period before the second recurrence decreased to 54.5 months (range 36–96 months).

Discussion

Epidermoids are benign lesions with rare reports of malignancy or malignant progression.7,13,44 There is no alter-
native to surgery for epidermoid cysts, especially in younger patients. Since the squamous stratified epithelium that constitutes the capsule is the real disease, total removal of the capsule is acknowledged to be the ultimate treatment. Because the capsule adheres to the brainstem, CNs, and perforating arteries, however, a conservative attitude toward removal has prevailed and many surgeons leave part of the capsule behind, accepting a higher risk of recurrence, especially for tumors extending into multiple sites. Deterred by the risk involved in dissecting the capsule, other authors have opted for a decompressive procedure by evacuating the contents or have not even attempted to handle the capsule.

With a capsule remnant, recurrence is inevitable with time, and the capsule cannot be totally removed in recurrent cases. The use of microsurgical techniques, skull base approaches, intraoperative neurophysiological monitoring, neuronavigation, and endoscope-assisted dissection facilitates complete removal of these lesions in many cases. Our study shows that total capsule excision can be done in a large number of cases and not only minimizes future recurrence but is also associated with fewer complications after the first surgery. This approach also eliminates the added morbidity of repeated surgery that has such a drastic impact on patient quality of life, especially since patients are relatively young at their first presentation.

Surgical Outcome and Extent of Tumor Resection

The early high rates of morbidity and mortality in patients with epidermoid tumors has fallen dramatically in the microsurgical era. The most frequent surgical complications are aseptic meningitis and multiple CN deficits. Some authors commonly believe that surgical complications can be decreased by avoiding dissection of the capsule that adheres to neurovascular structures. Lunar-di and colleagues concluded that the absence of operative mortality among patients who underwent subtotal removal and the late recurrence justify subtotal removal.

We attempted total removal, diligently pursuing the capsule not only to diminish the chance of recurrence, but also to reduce complications. It is well known that the remnants of capsule and cyst material are the main causes of the aseptic meningitis and hydrocephalus described in some reports. Our findings are supported by an analysis of major, modern large series reported in the literature. Tables 5–7 list 22 major reports divided into 3 groups to compare the postoperative results of different strategies related to the degree of tumor resection: Group 1: conservative, total removal in less than 25% of cases; Group 2: moderate, total removal in 25%–60% of cases; and Group 3: extensive, total removal in more than 60% of cases. The mean rate of total removal was 12% in the first group, 46% in the second, and 78% in the third.
Mortality rates appear higher in Group 1 and certainly not less in Group 2, compared with Group 3, in which aggressive attempts were made to achieve a high percentage of total removal. Aseptic meningitis is more common in patients undergoing conservative approaches, probably because of the residual lesion's continuous direct contact with brain tissue and CSF after partial or subtotal removal.\textsuperscript{14,24,40,44,51} This complication was almost absent in our series and has been less frequent in other contemporary reports with high rates of total removal and, perhaps, the routine prolonged use of high doses of corticosteroids.\textsuperscript{17,45}

A lower incidence of CN deficits was noted in a postoperative series with a high rate of total removal,\textsuperscript{32} but this result should be credited to the microsurgical techniques and intraoperative monitoring rather than to conservative handling of the capsule or the deliberate goal of subtotal removal.\textsuperscript{14,45,57} Furthermore, since our series comprised giant tumors that involved multiple CNs, at times bilaterally, and a relatively low rate of postoperative CN deficits, we believe that the skull base approach is an important factor in minimizing postoperative CN deficits.

**Neuroimaging**

Epidermoid tumors usually appear as a low-density mass on CT and have low signal intensity on T1-weighted MRI, high signal intensity on T2-weighted images, and hyperintensity on diffusion sequences with no enhancement.

| Table 4: Karnofsky Performance Scale scores for 31 patients* |
|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Group            | Time             | 100%            | 90%             | 80%             | 70%             | 60%             | 50%             |
| De novo (20 cases) | Preop            | 2               | 8               | 3               | 6               | 1               |
|                  | Immediate postop | 6               | 9               | 3               | 1               | 1               |
|                  | On FU            | 7               | 10              | 2               |                |                |
| Recurrence (11 cases) | Preop            | 1               | 3               | 7               |                |                |
|                  | Immediate postop | 1               | 4               | 5               | 1               |                |
|                  | On FU            | 2               | 3               | 5               | 1               |                |

FU = follow-up.

* Karnofsky Performance Scale score data were available in only 31 patients.
Calcification, hyperdensity, and marginal enhancement are rarely seen. Thus, these characteristics depict the contents of the cyst and aid in the accurate preoperative diagnosis. Postoperative imaging can only confirm removal of the cyst contents by the absence of hyperintensity on diffusion studies. Follow-up radiographic monitoring is crucial for detecting tumor recurrence through an increase in the size of residual lesions. Magnetic resonance imaging is the best modality for documenting tumor growth. Occasionally, partial or moderate rim enhancement has been reported, particularly with a recurrence, and is frequently caused by reactive granulation. Nonetheless, this enhancement has been thought to be an indication of neoplastic proliferation or a manifestation of malignancy. Our cases with obvious enhancement did not show signs of malignancy. Radiological confirmation of recurrence is not always easy. The cavity that remains after tumor has been excised fills with CSF, which appears on CT scans as a low-density area that resembles the original tumor and may be confused with recurrence. Multiple localizations on MRI and enhancement of the periphery further cloud the picture. Therefore, intervention for a recurrence should be based on documented clinical symptoms or a progressive, compressive accumulation seen on DWI, which can solely differentiate an epidermoid from a retained cyst or encephalomalacia, especially in patients with multiple recurrences.

Recurrence and Late Outcome

With a residual capsule, recurrence is inevitable given that the epidermoid cyst is a mere accumulation of cellular debris from a remnant of keratinized squamous epithelium. The variable rate of recurrence reported in the literature is attributed to a short follow-up period. As Tables 5–7 show, recurrence rates were lower in Group 3 (a higher rate of total removal) for comparable follow-up periods in the other groups.

Given a hypothesis of linear growth and a constant rate of debris accumulation, it is believed that the time required for the recurrence of a tumor the same size as the original is equal to the patient’s age at the initial surgery plus 9 months. Justifying the practice of subtotal removal and conservative handling of the capsule, this hypothesis assumes that as little as a single cell remains postoperatively and that the recurring mass grows at the same rate as the original tumor.

Multiple investigators suggest that the actual proliferation of this epithelium beyond the normal remnant should be considered a neoplasm, even with an incidence of malignant progression; hence, they should be treated the same as other benign tumors for which surgical removal is the goal. Echoing other authors, Altschuler and associates stated that repeated surgical attempts on these tumors are difficult and fraught with neurological complications for the patient. Repeated surgery is associated with accumulated deficits and morbidity and the expectation of another surgery. With repeated surgery, an inflammatory reaction with severe adhesion takes place, and the opportunity for total removal is lost. Moreover, the period between surgical interventions shortens with every recurrence. These findings emphasize that results are better and recurrence is delayed when resection of the tumor and capsule is as close to complete as possible.

One of the most important factors that facilitate total...
## TABLE 5. Literature summary of studies in which total removal occurred in less than 25% of cases, Group 1

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>Calcification (% cases)</th>
<th>No. of Cases</th>
<th>Total Removal (% cases)</th>
<th>Mortality (% cases)</th>
<th>Cyst Recurrence (% cases)</th>
<th>FU (yrs)</th>
<th>Aseptic Meningitis (% cases)</th>
<th>Complications (% cases)</th>
<th>Cranial Neuropathy cases (%)</th>
<th>Giant Tumor Occupying Multiple Compartments (% cases)</th>
<th>Supra- &amp; Infratentorial Extension (% cases)</th>
<th>Major Complaint</th>
<th>Use of Combined Techniques (% cases)</th>
<th>% Multi-Staged Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Berger &amp; Wilson, 1985</td>
<td>15.38</td>
<td>13</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>4.5</td>
<td>15.3</td>
<td>30.77</td>
<td>23.07</td>
<td>15.3</td>
<td>69.2</td>
<td>CMS, TN</td>
<td>7.69</td>
<td>7.69 PFA, FTA</td>
</tr>
<tr>
<td>Sabin et al., 1987</td>
<td>8.69</td>
<td>23</td>
<td>8.6</td>
<td>4.3</td>
<td>21.73</td>
<td>6</td>
<td>13.04</td>
<td>34.78</td>
<td>21.73</td>
<td>78.26</td>
<td>43.47</td>
<td>GA, HL, HA, Vo</td>
<td>30.43 PFA, TC</td>
<td>4.34 PFA, TC</td>
</tr>
<tr>
<td>de Souza et al., 1989</td>
<td>NA</td>
<td>27</td>
<td>18.51</td>
<td>3.7</td>
<td>14.81</td>
<td>5</td>
<td>11.11</td>
<td>37.03</td>
<td>18.5</td>
<td>14.8</td>
<td>14.8</td>
<td>FP, HL, Vo</td>
<td>14.81 PFA, MFA</td>
<td>NA</td>
</tr>
<tr>
<td>Vinchon et al., 1995</td>
<td>NA</td>
<td>9</td>
<td>0</td>
<td>22.2</td>
<td>0</td>
<td>3.05</td>
<td>22.2</td>
<td>55.5</td>
<td>33.33</td>
<td>4.44?</td>
<td>44.4</td>
<td>HL, CMS, HA</td>
<td>0</td>
<td>55.55 SRA, STA</td>
</tr>
<tr>
<td>Tancredi et al., 2003*</td>
<td>NA</td>
<td>9</td>
<td>22.2</td>
<td>11.11</td>
<td>33.33</td>
<td>14.5</td>
<td>33.3</td>
<td>33.3</td>
<td>11.1</td>
<td>66.66</td>
<td>NA</td>
<td>Vo, WD</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Desai et al., 2006†</td>
<td>8.33</td>
<td>24</td>
<td>25</td>
<td>0</td>
<td>4.16</td>
<td>5.2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>20.83</td>
<td>83.33</td>
<td>HA, A, VL</td>
<td>0</td>
<td>4.16 ISA, IPPOA</td>
</tr>
<tr>
<td>Mean</td>
<td>10.8</td>
<td>17.5</td>
<td>12.385</td>
<td>6.885</td>
<td>12.338</td>
<td>6.375</td>
<td>15.83</td>
<td>31.905</td>
<td>17.95</td>
<td>33.38</td>
<td>51.04</td>
<td></td>
<td>8.82</td>
<td>14.34</td>
</tr>
</tbody>
</table>

A = ataxia; CMS = cerebellopontine mass sign; FP = facial paralysis; FTA = frontotemporal approach; GA = gait ataxia; HA = headache; HL = hearing loss; IPPOA = interhemispheric posterior parietooccipital approach; ISA = infratentorial supracerebellar approach; MFA = middle fossa approach; NA = not available; PFA = posterior fossa approach; SRA = suboccipital retrosigmoid approach; STA = subtemporal approach; TC = temporal craniotomy; TN = trigeminal neuralgia; VL = visual loss; Vo = vertigo; WD = walking difficulty.

* Epidermoid cyst of the fourth ventricle.
† Pineal epidermoid cyst.
TABLE 6. Literature summary of studies in which total removal occurred in 28%–60% of cases, Group 2

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>Calcification (% cases)</th>
<th>No. of Cases</th>
<th>Total Removal (% cases)</th>
<th>Mortality (% cases)</th>
<th>Cyst Recurrence (% cases)</th>
<th>FU (yrs)</th>
<th>Aseptic Meningitis (% cases)</th>
<th>Complications (% cases)</th>
<th>Cranial Neuropathy (% cases)</th>
<th>Giant Tumor Occupying Multiple Compartments (% cases)</th>
<th>Supra- &amp; Infratentorial Extension (% cases)</th>
<th>Major Complaint</th>
<th>Use of Combined Techniques (% cases)</th>
<th>Major Complaint</th>
<th>Multi-Staged Cases (% cases)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yamakawa et al., 1989</td>
<td>15.15</td>
<td>33</td>
<td>36.4</td>
<td>12.12</td>
<td>24.13</td>
<td>8.83</td>
<td>12.12</td>
<td>35.7</td>
<td>15.15</td>
<td>15.15</td>
<td>12.12</td>
<td>T, S, GD, HA</td>
<td>NA</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Lunardi et al., 1990</td>
<td>NA</td>
<td>17</td>
<td>35.2</td>
<td>17.6</td>
<td>11.7</td>
<td>9</td>
<td>17.6</td>
<td>17.6</td>
<td>17.6</td>
<td>NA</td>
<td>NA</td>
<td>CMS, TN, HS</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Altschuler et al., 1990</td>
<td>7.69</td>
<td>13</td>
<td>54</td>
<td>0</td>
<td>15.38</td>
<td>4.6</td>
<td>0</td>
<td>30.76</td>
<td>15.38</td>
<td>30.76</td>
<td>38.46</td>
<td>GD, HA</td>
<td>7.69 RMA, FTA</td>
<td>7.69</td>
<td></td>
</tr>
<tr>
<td>Mohanty et al., 1997</td>
<td>8</td>
<td>25</td>
<td>48</td>
<td>8</td>
<td>0</td>
<td>3.6</td>
<td>8</td>
<td>56</td>
<td>20</td>
<td>100</td>
<td>76</td>
<td>CMS, CN5, CN7, FP, HL</td>
<td>4 RMA, STA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Talacchi et al., 1998</td>
<td>17.85</td>
<td>28</td>
<td>57</td>
<td>3.5</td>
<td>30</td>
<td>8.6</td>
<td>14.3</td>
<td>28.57</td>
<td>10.7</td>
<td>60.7</td>
<td>60.7</td>
<td>HA, T</td>
<td>10.71</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Kaspera et al., 1999</td>
<td>NA</td>
<td>17</td>
<td>50</td>
<td>11.7</td>
<td>16.7</td>
<td>3.3</td>
<td>7</td>
<td>NA</td>
<td>13</td>
<td>NA</td>
<td>23.5</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Kobata et al., 2002</td>
<td>6.66</td>
<td>30</td>
<td>56.7</td>
<td>0</td>
<td>6</td>
<td>11.5</td>
<td>6.6</td>
<td>53.33</td>
<td>10</td>
<td>NA</td>
<td>NA</td>
<td>CN5, HS</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Goel et al., 2006</td>
<td>5.20</td>
<td>96</td>
<td>48</td>
<td>2.1</td>
<td>2.1</td>
<td>4.3</td>
<td>2.1</td>
<td>5.2</td>
<td>23.9</td>
<td>87.5</td>
<td>87.5</td>
<td>HA, GD</td>
<td>2.08</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Ahmed et al., 2009*</td>
<td>NA</td>
<td>7</td>
<td>28.6</td>
<td>0</td>
<td>28.6</td>
<td>4.9</td>
<td>28.6</td>
<td>71.4</td>
<td>42.8</td>
<td>57.14</td>
<td>0</td>
<td>HA</td>
<td>NA</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>10.09</td>
<td>29.56</td>
<td>45.99</td>
<td>6.11</td>
<td>14.96</td>
<td>6.51</td>
<td>10.7</td>
<td>37.32</td>
<td>18.73</td>
<td>58.54</td>
<td>49.71</td>
<td>6.12</td>
<td>1.54</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CN5, CN7 = deficits in cranial nerves 5, 7; GD = gait disturbance; RMA = retromastoid approach; S = seizure; T = tinnitus.
* Epidermoid tumors in 3 children.
## TABLE 7. Literature summary of studies in which total removal occurred in 62% or more cases, Group 3

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>Calcification (% cases)</th>
<th>No. of Cases</th>
<th>Total Removal (% cases)</th>
<th>Mortality (% cases)</th>
<th>Cyst Recurrence (% cases)</th>
<th>FU (yrs)</th>
<th>Aseptic Meningitis (% cases)</th>
<th>Complications (% cases)</th>
<th>Cranial Neuropathy (% cases)</th>
<th>Giant Tumor Occupying Multiple Compartments (% cases)</th>
<th>Supra- &amp; Infratentorial Extension (% cases)</th>
<th>Major Complaint</th>
<th>Use of Combined Techniques (% cases)</th>
<th>% Multi-Staged Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yapargil et al., 1989</td>
<td>5.71</td>
<td>35</td>
<td>97</td>
<td>4.65</td>
<td>0</td>
<td>5.2</td>
<td>18.06</td>
<td>30.23</td>
<td>20.43</td>
<td>100</td>
<td>20</td>
<td>HA, Di</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fornari et al., 1990</td>
<td>9.09</td>
<td>14</td>
<td>85.6</td>
<td>7.1</td>
<td>7.1</td>
<td>13</td>
<td>7.1</td>
<td>14.2</td>
<td>14.2</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Vi, S</td>
<td>0</td>
</tr>
<tr>
<td>Samii et al., 1996</td>
<td>NA</td>
<td>40</td>
<td>75</td>
<td>2.5</td>
<td>7.5</td>
<td>5.7</td>
<td>2.5</td>
<td>17.5</td>
<td>10</td>
<td>NA</td>
<td>62.5</td>
<td>HL, Di</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Darrouzet et al., 2004</td>
<td>NA</td>
<td>8</td>
<td>62.5</td>
<td>0</td>
<td>0</td>
<td>3.7</td>
<td>12.5</td>
<td>50</td>
<td>50</td>
<td>100</td>
<td>NA</td>
<td>HA, Deq</td>
<td>25</td>
<td>0</td>
</tr>
<tr>
<td>Kaylie et al., 2005</td>
<td>NA</td>
<td>10</td>
<td>80</td>
<td>10</td>
<td>10</td>
<td>1.75</td>
<td>0</td>
<td>40</td>
<td>40</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>HL, HA, Vo</td>
<td>50 TL+TC</td>
</tr>
<tr>
<td>Safavi-Abbasi et al., 2008</td>
<td>NA</td>
<td>12</td>
<td>75</td>
<td>0</td>
<td>0</td>
<td>2.25</td>
<td>0</td>
<td>8.33</td>
<td>8.33</td>
<td>83.33</td>
<td>8.33</td>
<td>PyS/CMS, HA</td>
<td>8.33</td>
<td>8.33</td>
</tr>
<tr>
<td>Chowdhury et al., 2013</td>
<td>4.35</td>
<td>23</td>
<td>73.9</td>
<td>8.7</td>
<td>0</td>
<td>3.25</td>
<td>0</td>
<td>21.74</td>
<td>13.04</td>
<td>NA</td>
<td>13.04</td>
<td>HA, Vo</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Mean</td>
<td>6.38</td>
<td>20.23</td>
<td>78.43</td>
<td>4.7</td>
<td>3.51</td>
<td>4.98</td>
<td>5.74</td>
<td>26</td>
<td>22.29</td>
<td>94.44</td>
<td>25.97</td>
<td>13.89</td>
<td>1.39</td>
<td></td>
</tr>
</tbody>
</table>

Deq = disequilibrium; Di = dizziness; LSOA = lateral suboccipital approach; PyS = pyramidal sign/cerebellar; TL = translabyrinthine; Vi = visual disturbances including restriction of eye movements.
removal is adequate exposure of the lesion.\textsuperscript{32,49,51} In the patients who came to us with a recurrence, exposure during the previous surgery had been limited and did not allow access to all extensions of the tumor, preventing the surgeon from resecting the capsule in these regions. We extended the previous approaches with wide skull base exposures\textsuperscript{4} to allow better access to all portions of the tumor.

**Giant Tumors and Extent of Resection**

Both old and recent series in the literature include some cases of giant tumors that extend into multiple compartments.\textsuperscript{4,40,44} These tumors are formidable, and the goal of total removal of the capsule is quite challenging. These cases have been fraught with a high risk of failure and recurrence.\textsuperscript{40,44} In such cases, surgeons have resorted to subtotal resection or a staged operation through 2 different approaches: the use of an endoscope to visualize beyond the restrictive limits of the traditional approach or the use of a combined infra- and supratentorial approach.\textsuperscript{15,44,48} Altschuler and colleagues\textsuperscript{4} found that patients who required multiple procedures resulting in fixed deficits had an extensive lesion and incomplete initial resection, which they believed to be attributable to a limited initial exposure. They contemplated whether the use of a more extensive approach in a first operation would have resulted in better tumor resection, improved outcome, and reduced recurrence.

We strongly believe, and the results of our study confirm, that full exposure through a skull base approach not only increases the likelihood of total removal of this lesion, including the capsule, but also alleviates operative complications, CN deficits, and aseptic meningitis. Our findings support the role of a skull base approach in effectively and safely removing the capsule.

**Conclusions**

Total removal and complete resection of the capsule can be achieved in the majority of patients with giant epidermoids and is associated with low morbidity and mortality. This goal is facilitated by a thorough preoperative evaluation, an approach that allows wide exposure, sharp microsurgical removal, extensive intraoperative CN monitoring, an endoscope-assisted technique, and neuronavigation. The pursuit of total capsule removal minimizes not only recurrences but also the risk of postoperative aseptic meningitis, CN deficits, and subsequent complications from repeated surgery for recurrences.

**Acknowledgments**

We are grateful to Dr. Linda Bi and Julie Yamamoto for editorial assistance.

**References**

25. Hamlat A, Hua ZF, Saikali S, Egretaue J, Guegan Y: Malig-
taneous transformation of intracranial epidermoid cyst with lep-
29. Karantanas AH: MR imaging of intracranial epidermoid tu-
32. Kaylie DM, Warren FM III, Haynes DS, Jackson CG: Neu-
34. King JE: Extradural diploic and intradural epidermoid tu-
35. Kobata H, Kondo A, Iwasaki K: Cerebellopontine angle epidermoids presenting with cranial nerve hypertensive dys-
41. Olson JJ, Beck DW, Crawford SC, Menezes AH: Compari-
44. Sabin H, Bordi LT, Symon L: Epidermoid cysts and cho-
46. Samii M, Tatagiba M, Piquer J, Carvalho GA: Surgical treat-
ment of epidermoid cysts of the cerebellopontine angle. J Neurosurg 84:14–19, 1996
47. Sawan B, Vital A, Loiseau H, Dousset V, Strub D, Vital C: Squamous cell carcinoma developing in an intracranial pre-
48. Schroeder HW, Oertel J, Gaab MR: Endoscope-assisted microsurgical resection of epidermoid tumors of the cerebel-
49. Shimamoto Y, Kawase T, Sasaki H, Shiobara R, Yamada F: Anterior transpetrosal approach to the preoptic epider-
51. Talacchi A, Sala F, Alessandini F, Turazzi S, Bricolo A: As-
sessment and surgical management of posterior fossa epider-
53. Toglia JU, Netsky MG, Alexander E Jr: Epithelial (epider-
57. Yaşargil MG, Abernathey CD, Sarioglu AC: Microneuro-
surgical resection of epidermoid tumors of the cerebel-
58. Yasargil MG, Abernathey CD, Sarioglu AC: Microneuro-

Author Contributions
Conception and design: Al-Mefty, Aboud. Acquisition of data: all authors. Analysis and interpretation of data: Al-Mefty, Aboud, Abolfotoh, Pravdenkova, Gokoglu. Drafting the article: Al-Mefty, Aboud, Abolfotoh. Reviewed the submitted version of manuscript: Al-Mefty, Aboud, Abolfotoh. Pravdenkova, Gokoglu. Approved the final version of the manuscript on behalf of all authors: Al-Mefty. Statistical analysis: Al-Mefty, Abolfotoh, Pravdenkova. Administrative/technical/material support: Al-Mefty. Study supervision: Al-Mefty.

Correspondence
Ossama Al-Mefty, Department of Neurosurgery, Brigham and Women’s Hospital, 75 Francis St., Boston, MA 02115. email: oalmefty@partners.org.